• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Cingulate Inc.

    8/15/25 9:09:25 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CING alert in real time by email
    NT 10-Q 1 formnt10-q.htm NT 10-Q

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    (Check one):

    ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q

    ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR

       
      For Period Ended: June 30, 2025
       
      ☐ Transition Report on Form 10-K
      ☐ Transition Report on Form 20-F
      ☐ Transition Report on Form 11-K
      ☐ Transition Report on Form 10-Q
      ☐ Transition Report on Form N-SAR
       
      For the Transition Period Ended:

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

    PART I — REGISTRANT INFORMATION

     

    Cingulate Inc.

    Full Name of Registrant

     

    Not Applicable

    Former Name if Applicable

     

    1901 W. 47th Place

    Address of Principal Executive Office (Street and Number)

     

    Kansas City, KS 66205

    City, State and Zip Code

     

     

     

     

     

     

    PART II — RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

      (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
         
    ☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
         
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III — NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    Cingulate Inc. (the “Company”) plans to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) as soon as practicable and within the five calendar day period provided by Rule 12b-25 for delayed filings. The Company requires additional time to complete the review of its financial statements for the quarter ended June 30, 2025, due to recent changes in the Company’s management which are described in the Company’s Current Report on Form 8-K filed with the SEC on August 15, 2025, which have resulted in additional time being required to complete the preparation and review of the Company’s financial statements and related disclosures, and the Company cannot, without unreasonable effort or expense, file the Form 10-Q on the original due date. The Company anticipates that it will be able to file the Form 10-Q within the extension period provided under Rule 12b-25.

     

    PART IV — OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification:
       
      Jennifer L. Callahan   (913)   942-2300
      (Name)   (Area Code)   (Telephone Number)
       
    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No
       
    (3)

    Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

    ☐ Yes ☒ No

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

     

     

    Cingulate Inc.

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: August 15, 2025 By: /s/ Jennifer L. Callahan
        Jennifer L. Callahan
      Title: Interim Chief Executive Officer & Chief Financial Officer

     

     

     

    Get the next $CING alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CING

    DatePrice TargetRatingAnalyst
    1/10/2025$12.00Buy
    ROTH MKM
    12/22/2023Buy → Hold
    Laidlaw
    1/20/2022$8.50Buy
    Laidlaw & Co.
    1/11/2022$9.00Buy
    Aegis Capital
    More analyst ratings

    $CING
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Callahan Jennifer L. bought $1,490 worth of shares (55 units at $27.10), increasing direct ownership by 2% to 2,333 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    3/22/24 6:00:15 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Callahan Jennifer L. bought $3,348 worth of shares (5,000 units at $0.67), increasing direct ownership by 12% to 45,508 units

    4 - Cingulate Inc. (0001862150) (Issuer)

    9/18/23 6:00:26 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CLO and CCO Patel Nilay Dahyabhai

    4 - Cingulate Inc. (0001862150) (Issuer)

    7/10/25 6:02:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Patel Nilay Dahyabhai

    3 - Cingulate Inc. (0001862150) (Issuer)

    7/10/25 6:00:15 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP and CSO Silva Raul R.

    4 - Cingulate Inc. (0001862150) (Issuer)

    7/9/25 6:00:13 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Cingulate with a new price target

    ROTH MKM initiated coverage of Cingulate with a rating of Buy and set a new price target of $12.00

    1/10/25 7:39:52 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate downgraded by Laidlaw

    Laidlaw downgraded Cingulate from Buy to Hold

    12/22/23 7:22:08 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Laidlaw & Co. initiated coverage on Cingulate with a new price target

    Laidlaw & Co. initiated coverage of Cingulate with a rating of Buy and set a new price target of $8.50

    1/20/22 9:15:46 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

    Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026 KANSAS CITY, Kan., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended June 30, 2025, and provided recent highlights. Recent Highlights: On July 31, 2025, Cingulate submitted its NDA to the FDA for CTx-1301, a novel, extended-release tablet formulation

    8/19/25 8:45:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Provides Management Team Update

    Jennifer Callahan, Chief Financial Officer, appointed Interim CEO Board member, Jay Roberts appointed Executive Chairman KANSAS CITY, Kan., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:CING) The Board of Directors of Cingulate Inc. ("Cingulate") announced that it has placed Chairman and Chief Executive Officer, Shane J. Schaffer, PharmD, on administrative leave in connection with ongoing legal matters unrelated to the company and its operations. In addition, Jennifer Callahan, Cingulate's Chief Financial Officer, has been appointed interim CEO to ensure business continuity and operational stability. Ms. Callahan will retain her responsibilities as Chief Financial Officer. Healthcare in

    8/15/25 9:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

    KANSAS CITY, Kan., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for CTx-1301(dexmethylphenidate HCl), the company's lead asset for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). CTx-1301 is a novel, extended-release tablet formulation of dexmethylphenidate designed to deliver fast onset, entire active-day efficacy, and a smooth pharmacokinet

    8/6/25 8:45:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Financials

    Live finance-specific insights

    View All

    Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

    Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026 KANSAS CITY, Kan., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended June 30, 2025, and provided recent highlights. Recent Highlights: On July 31, 2025, Cingulate submitted its NDA to the FDA for CTx-1301, a novel, extended-release tablet formulation

    8/19/25 8:45:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

    Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025 Non-Dilutive Funding to Accelerate Development of CTx-2103 (buspirone) KANSAS CITY, Kan., May 08, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended March 31, 2025, and provided a clinical and business update. Highlights include the completion of the Pre-NDA meeting for CTx-1301 and grant received to accelerate

    5/8/25 4:30:00 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

    KANSAS CITY, Kan., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three months ended September 30, 2024, and provided a clinical and business update. "The capital raised this quarter has allowed us to focus on advancing the remaining activities required for NDA submission of our lead ADHD asset, CTx-1301, targeted for mid 2025," said Cingulate Chairman and CEO Shane J. Schaffer. "The granting of European patents for CTx-1301 in up to

    11/7/24 7:30:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Leadership Updates

    Live Leadership Updates

    View All

    Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application

    KANSAS CITY, Kan., July 09, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, has named Nilay Patel, JD, as Chief Legal Officer. Patel's appointment comes as Cingulate plans to submit a new drug application to the FDA in coming weeks for its lead asset CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Mr. Patel brings more than two decades of legal and compliance leadership in the pharmaceutical industry, having advised companies across

    7/9/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer

    Industry Leader with 30+ Years of Experience Will Drive Strategic Growth and Partnerships SCOTTSDALE, Ariz., May 27, 2025 /PRNewswire/ -- Life365, a leading data engagement and virtual care company, today announced the appointment of healthcare executive and investor Jay Roberts as chief development officer. Roberts, who previously served as an executive advisor to Life365, brings more than 30 years of strategic healthcare leadership experience to this pivotal role. Life365's platform enables the next generation of AI-driven healthcare for enterprise healthcare organizations,

    5/27/25 10:05:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

    KANSAS CITY, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has appointed three new directors to its board: Jay Roberts, Bryan Lawrence, and Jeff Ervin. The appointment of the new directors follows the completion of the Company's recent follow-on offering of $7.5 million in February 2024, sales under the Company's at-the-market offering (ATM) facility in January 2024 of $3.2 million, as well as the conversion of $3.3 million of outstanding debt i

    2/13/24 6:45:00 AM ET
    $BACK
    $CING
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $CING
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cingulate Inc.

    SC 13G/A - Cingulate Inc. (0001862150) (Subject)

    11/14/24 7:21:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cingulate Inc.

    SC 13D/A - Cingulate Inc. (0001862150) (Subject)

    8/30/24 6:00:22 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cingulate Inc.

    SC 13D/A - Cingulate Inc. (0001862150) (Subject)

    8/20/24 7:00:06 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    SEC Filings

    View All

    SEC Form 10-Q filed by Cingulate Inc.

    10-Q - Cingulate Inc. (0001862150) (Filer)

    8/19/25 8:56:21 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Cingulate Inc. (0001862150) (Filer)

    8/19/25 8:50:51 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Cingulate Inc.

    DEF 14A - Cingulate Inc. (0001862150) (Filer)

    8/15/25 4:30:24 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care